CVS/Caremark settles with states
Executive Summary
Firm settles multi-state consumer protection investigation into PBM practices, including therapeutic switching by its legacy AdvancePCS and Caremark subsidiaries by agreeing to payments of up to $41 million. Led by the Illinois and Maryland attorneys general, the investigation by a total of 28 states began in 2004. Of the total payment amount, $38.5 million will go to the states and up to $2.5 million will be allocated to patients who had to undergo medical tests related to switches of cholesterol-reducing drugs. A consent order also restricts therapeutic interchanges by the PBM and requires greater transparency from the company regarding its incentives for switches. CVS/Caremark maintains the agreement involves no admission of wrongdoing on its part. The firm settled federal charges against its legacy subsidiaries in 2005 (1"The Pink Sheet," Sept. 12, 2005, p. 13)...
You may also be interested in...
Caremark False Claims Act Settlement Could Be Framework For State Cases
Caremark's focus on resolving allegations of kickbacks and false claims related to its AdvancePCS subsidiary is expected to shift to state investigations following a $137.5 mil. settlement with federal prosecutors
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.